Alirocumab

Alirocumab is a human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), a circulating protein that modulates the activity of the LDL cholesterol receptor in the liver. The monoclonal antibody lowers serum LDL cholesterol and is used to treat severe hypercholesterolemia. Alirocumab therapy has been associated with a low rate of serum aminotransferase elevations and has yet to be linked to instances of clinically apparent acute liver injury.


Cat. No.: EX-A4627	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
10mg	1085	In-stock
25mg	1585	In-stock
50mg	2285	In-stock
100mg	3185	In-stock
200mg	Get quote	In-stock
500mg	Get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Molecular Formula: C6472H9996N1736O2032S42
CAS No.	1245916-14-6
Purity	>98%
Formula	C6472H9996N1736O2032S42
Appearance	colourless to light yellow (liquid)
Shelf Life	>3 years if stored properly
Storage	Pure -30℃ 3 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. Shipping with ice bag upon request

Reference:	[1]. Ramanathan, Aarti et al. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. PloS one vol. 11,4 e0154498. 26 Apr. 2016, doi:10.1371/journal.pone.0154498
CoA	CoA of Alirocumab


		Search